Opendata, web and dolomites

OXIFLOW SIGNED

Next Generation Flow Diverter for the Treatment of Intracranial Aneurysms Delivering Improved Patient Outcomes and Healthcare Cost Savings

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OXIFLOW project word cloud

Explore the words cloud of the OXIFLOW project. It provides you a very rough idea of what is the project "OXIFLOW" about.

minimally    tortuous    optimum    coiling    uniform    transfer    healing    radial    ias    severe    vessels    generating    period    reporting    delivering    causes    manufacture    citizens    freeze    innovative    utilises    cheaper    addressable    51    40    inferior    haemorrhage    avoidable    entirely    disabilities    procedure    regulatory    pilot    sah    apposition    forces    risky    options    endovascular    oe    whom    intracranial    expensive    ing    weak    poorer    business    excellent    die    nitinol    overcoming    failed    whilst    away    material    fds    blood    market    ethical    cumulative    man    guidewire    56m    safety    inherent    flow    extension    memory    risk    made    mesh    invasive    expectations    porosity    divert    poor    fd    central    lower    vessel    clipping    complete    live    principles    revenues    surgical    rupture    subarachnoid    performance    thereby    diverters    first    aneurysm    treatment    approvals    suffer    patient    unruptured    73    limitations    oxiflow    coning    device    restrict    resolution    02m    origami    ia    natural    shape    clinical    each    fim    463m    small   

Project "OXIFLOW" data sheet

The following table provides information about the project.

Coordinator
OXFORD ENDOVASCULAR LIMITED 

Organization address
address: 9400, GARSINGTON ROAD, OXFORD
city: OXFORD
postcode: OX4 2HN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 4˙232˙828 €
 EC max contribution 2˙962˙979 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OXFORD ENDOVASCULAR LIMITED UK (OXFORD) coordinator 2˙962˙979.00

Map

 Project objective

Each year ~51,000 EU citizens suffer a subarachnoid haemorrhage (SAH) resulting from the rupture of an intracranial aneurysm (IA), of whom 40% will die and 40% will suffer severe disabilities. However, SAH’s are entirely avoidable through treatment of ‘at risk’ unruptured IAs.

Existing treatment options include: surgical clipping, an invasive, risky and expensive procedure but delivering excellent long-term resolution; and endovascular coiling, a cheaper and lower risk minimally invasive procedure but delivering poorer long-term resolution. Flow diverters (FDs) are an emerging endovascular device that divert blood flow away from the aneurysm thereby enabling natural healing. Whilst offering the potential of excellent long-term resolution at low risk and cost, existing FDs have failed to live up to expectations, reporting performance inferior to coiling. Limitations of existing FD’s are inherent to their mesh design that causes weak and non-uniform radial forces resulting in poor vessel apposition, variable porosity and device coning. Existing delivery systems also restrict use due to extension of the central guidewire during delivery.

OxiFlow is a unique FD design based on origami principles and made from a shape memory Nitinol material. The innovative design enables optimum and uniform radial forces thereby overcoming the limitations of existing FDs. Furthermore, OxiFlow utilises a novel delivery system enabling complete user control of the central guidewire extension and thus use in small and tortuous vessels.

OXIFLOW will evaluate safety and performance of the OxiFlow device through a 10-patient First-in-Man (FIM) study. Project activities include: device design freeze, transfer to pilot scale manufacture, pre-clinical testing; regulatory and ethical approvals; and FIM study implementation.

The addressable EU & US market for OxiFlow is estimated at €463M. OE target €40.02M business growth over a 5-year period generating €73.56M cumulative revenues.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIFLOW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIFLOW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More  

MEDIVAC (2019)

Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Read More  

Manuback (2019)

MANUBACK, the smart garment for operator protection in the field of Manual Handling of Goods

Read More